Rallybio Corporation (RLYB)

Market Cap	10.42M
Revenue (ttm)	636,000
Net Income (ttm)	-57.78M
Shares Out	41.61M
EPS (ttm)	-1.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	86,399
Open	0.2630
Previous Close	0.2506
Day's Range	0.2390 - 0.2631
52-Week Range	0.2200 - 2.7700
Beta	-1.35
Analysts	Buy
Price Target	11.33 (+4,426.57%)
Earnings Date	May 8, 2025

About RLYB

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 29, 2021
• Employees: 25
• Stock Exchange: NASDAQ
• Ticker Symbol: RLYB
• Website: https://www.rallybio.com

Analyst Forecast

According to 5 analysts, the average rating for RLYB stock is "Buy." The 12-month stock price forecast is $11.33, which is an increase of 4,426.57% from the latest price.

Price Target

$11.33

(4,426.57% upside)

Analyst Consensus: Buy